Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

J. K. Hicks; K. Sangkuhl; J. J. Swen; V. L. Ellingrod; D. J. Müller; K. Shimoda; J. R. Bishop; E. D. Kharasch; T. C. Skaar; A. Gaedigk; H. M. Dunnenberger; T. E. Klein; K. E. Caudle; J. C. Stingl

doi:10.1002/cpt.597

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

J. K. Hicks, K. Sangkuhl, J. J. Swen, V. L. Ellingrod, D. J. Müller, K. Shimoda, J. R. Bishop, E. D. Kharasch, T. C. Skaar, A. Gaedigk, H. M. Dunnenberger, T. E. Klein, K. E. Caudle, J. C. Stingl

Experimental and Clinical Pharmacology

Research output: Contribution to journal › Article › peer-review

432 Scopus citations

Original language	English (US)
Pages (from-to)	37-44
Number of pages	8
Journal	Clinical pharmacology and therapeutics
Volume	102
Issue number	1
DOIs	https://doi.org/10.1002/cpt.597
State	Published - Jul 1 2017

Bibliographical note

Funding Information:
We acknowledge the critical input of Dr. M. Relling and members of the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network, funded by the National Institutes of Health. This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374). E.D.K. is supported by R01 GM63674 and R01 DA14211. T.C.S. is supported by R01 GM088076 and the Agency for Healthcare Research and Quality (R01 HS19818-01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. V.L.E. is supported by the NIMH (R01 MH082784). D.J.M. is supported by a New Investigator Salary Award from the Canadian Institutes of Health Research, a New Investigator Fellowship Award from the Ontario Mental Health Foundation, and an Early Researcher Award by the Ministry of Research and Innovation of Ontario. A.G. is supported by R01 GM088076-05.

Access

10.1002/cpt.597

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479

OpenUrl availability

Full text

Cite this

Hicks, J. K., Sangkuhl, K., Swen, J. J., Ellingrod, V. L., Müller, D. J., Shimoda, K., Bishop, J. R., Kharasch, E. D., Skaar, T. C., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Caudle, K. E., & Stingl, J. C. (2017). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clinical pharmacology and therapeutics, 102(1), 37-44. https://doi.org/10.1002/cpt.597

Hicks, JK, Sangkuhl, K, Swen, JJ, Ellingrod, VL, Müller, DJ, Shimoda, K, Bishop, JR, Kharasch, ED, Skaar, TC, Gaedigk, A, Dunnenberger, HM, Klein, TE, Caudle, KE & Stingl, JC 2017, 'Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update', Clinical pharmacology and therapeutics, vol. 102, no. 1, pp. 37-44. https://doi.org/10.1002/cpt.597

@article{efc3f468296f4f65829445a4378f1f70,

title = "Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update",

author = "Hicks, {J. K.} and K. Sangkuhl and Swen, {J. J.} and Ellingrod, {V. L.} and M{\"u}ller, {D. J.} and K. Shimoda and Bishop, {J. R.} and Kharasch, {E. D.} and Skaar, {T. C.} and A. Gaedigk and Dunnenberger, {H. M.} and Klein, {T. E.} and Caudle, {K. E.} and Stingl, {J. C.}",

note = "Funding Information: We acknowledge the critical input of Dr. M. Relling and members of the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network, funded by the National Institutes of Health. This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374). E.D.K. is supported by R01 GM63674 and R01 DA14211. T.C.S. is supported by R01 GM088076 and the Agency for Healthcare Research and Quality (R01 HS19818-01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. V.L.E. is supported by the NIMH (R01 MH082784). D.J.M. is supported by a New Investigator Salary Award from the Canadian Institutes of Health Research, a New Investigator Fellowship Award from the Ontario Mental Health Foundation, and an Early Researcher Award by the Ministry of Research and Innovation of Ontario. A.G. is supported by R01 GM088076-05.",

year = "2017",

month = jul,

day = "1",

doi = "10.1002/cpt.597",

language = "English (US)",

volume = "102",

pages = "37--44",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

T2 - 2016 update

AU - Hicks, J. K.

AU - Sangkuhl, K.

AU - Swen, J. J.

AU - Ellingrod, V. L.

AU - Müller, D. J.

AU - Shimoda, K.

AU - Bishop, J. R.

AU - Kharasch, E. D.

AU - Skaar, T. C.

AU - Gaedigk, A.

AU - Dunnenberger, H. M.

AU - Klein, T. E.

AU - Caudle, K. E.

AU - Stingl, J. C.

N1 - Funding Information: We acknowledge the critical input of Dr. M. Relling and members of the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network, funded by the National Institutes of Health. This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374). E.D.K. is supported by R01 GM63674 and R01 DA14211. T.C.S. is supported by R01 GM088076 and the Agency for Healthcare Research and Quality (R01 HS19818-01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. V.L.E. is supported by the NIMH (R01 MH082784). D.J.M. is supported by a New Investigator Salary Award from the Canadian Institutes of Health Research, a New Investigator Fellowship Award from the Ontario Mental Health Foundation, and an Early Researcher Award by the Ministry of Research and Innovation of Ontario. A.G. is supported by R01 GM088076-05.

PY - 2017/7/1

Y1 - 2017/7/1

UR - http://www.scopus.com/inward/record.url?scp=85013115073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013115073&partnerID=8YFLogxK

U2 - 10.1002/cpt.597

DO - 10.1002/cpt.597

M3 - Article

C2 - 27997040

AN - SCOPUS:85013115073

SN - 0009-9236

VL - 102

SP - 37

EP - 44

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 1

ER -

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

Bibliographical note

Access

OpenUrl availability

Other files and links

Cite this